Sign in Subscribe
Pharmaceutical industry

Biogen and Elan Collaborate on Antegren Development

Strategic Insights

— 1 min read

Biogen and Elan announced a collaboration to develop, manufacture, and commercialize Antegren, a humanized monoclonal antibody currently in Phase 2 clinical trials for multiple sclerosis and Crohn's disease. This announcement marks the beginning of a new class of agents with potential uses in various diseases. The collaboration will share costs and benefits, with upfront and milestone payments recognizing the value each party brings to the collaboration. The partnership aims to bring this groundbreaking drug to patients as quickly as possible, with both companies being pioneers in VLA-4 biology and research.

Key Takeaways:

  • Biogen and Elan have entered into a worldwide, exclusive collaboration to develop, manufacture, and commercialize Antegren, a new class of agents with potential uses in various diseases.
  • Antegren is a humanized monoclonal antibody currently in Phase 2 clinical trials for multiple sclerosis and Crohn's disease.
  • The collaboration will share costs for ongoing development activities and economic benefits from Antegren commercialization.
  • Biogen and Elan will work together to develop and commercialize Antegren, with financial details of the agreement including upfront and milestone payments.
  • Antegren demonstrated promising results in Phase 2 studies in MS and encouraging data in separate trials with Crohn's disease and ulcerative colitis patients.
  • The partnership aims to bring this groundbreaking drug to patients as quickly as possible, leveraging the companies' research and development expertise.
  • Biogen and Elan are pioneers in VLA-4 biology and research, which will be highly synergistic in the challenges of completing the development and successful introduction of Antegren.

Statistics:

  • Antegren is currently in Phase 2 clinical trials.
  • The collaboration will share costs for ongoing development activities.
  • Upfront and milestone payments will be made as part of the agreement.
  • Biogen revenue is generated from U.S. and European sales of AVONEX.
  • Elan's principal research and manufacturing facilities are in Ireland, the United States, and Israel.
  • Elan shares trade on the New York, London, and Dublin Stock Exchanges.

Sources:

  • Biogen, Inc. press release, August 17, 1999.
  • Elan Corporation, plc. press release, August 17, 1999.

Read more